Buddy-In
neudive.com
- iPhone and iPad
- Android
5.9 Club score Visit neudive.com
What the maker publishes
- Clinical evidence
- Neudive says exploratory and confirmatory clinical trials were completed and found safety and improvement in Adaptive Behavior Composite score versus control. source
- Clinician monitoring
- The system records usage, performance, and training progress for clinicians to monitor in real time. source
- Founded
- 2022 source
- Headquarters
- Daegu, South Korea source
- Maker
- Neudive says it was founded in 2022 and lists its headquarters in Daegu, South Korea. source
- Medical-device certification
- Buddy-In received MFDS manufacturing certification as a Class II digital medical device on May 7, 2026. source
- Parent reports
- Parents receive reports about what their child is learning and changes in social skills over time. source
- Personalized scenarios
- Mobile scenario-based games and an algorithm-driven structure tailor training to each user's level. source
- Prescription
- Buddy-In is prescribed by a medical professional following diagnosis and assessment of suitability. source
- Purpose
- Buddy-In is a digital medical device for social-skills training for children and adolescents aged 10–18 with ASD or Social (Pragmatic) Communication Disorder. source
- Support
- Neudive lists weekday support hours of 09:00–18:00 and provides a phone number and email address. source
- Therapy approach
- Buddy-In is based on Cognitive Behavioral Therapy and Social Skills Training. source
- Training schedule
- The program is designed for 30 sessions over six weeks, five times a week, for about 10 minutes per session. source
- Use alongside treatment
- Buddy-In is intended to complement, not replace, existing treatment or in-person support. source
- Use caution
- The maker recommends guardian monitoring and stopping use if discomfort or unusual behavior occurs. source
Checked against the maker's pages on 14 Nov 2026.